

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims:**

Claim 1 (previously presented): An isolated antibody which reduces the level of hyaluronan synthase (HAS) activity wherein said antibody specifically targets SEQ ID NO:25 within an HAS.

Claim 2 (currently amended): The isolated antibody of claim 1 wherein the HAS is selected from the group consisting of HAS1, HAS2 and HAS3.

Claims 3-11 (canceled)

Claim 12 (previously presented): The isolated antibody of claim 1 or 2 wherein the antibody is selected from a monoclonal antibody, polyclonal antibody, and antigen-binding fragment and a humanized antibody.

Claim 13 (previously presented): The isolated antibody of claim 12 wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof.

Claim 14 (canceled)

Claim 15 (withdrawn): The isolated compound of claim 1 or 2 when used in the treatment of cancer, a hyperproliferative condition or an inflammatory condition.

Claim 16 (withdrawn – currently amended): A pharmaceutical composition comprising an antibody of claim 1 ~~a compound of any one of claims 1 to 14~~ and one or more pharmaceutically acceptable carriers and/or diluents.

Claim 17 (withdrawn – currently amended): A method for the treatment or prophylaxis of a condition in a subject, said method comprising administering to said subject,

an effective amount of an antibody of claim 1 ~~a compound of any one of claims 1 to 14~~ for reducing the level and/or activity of HAS.

Claim 18 (withdrawn): The method of claim 17 wherein the subject is a human.

Claim 19 (canceled)

Claim 20 (withdrawn –currently amended): The method of claim 17 [[or 18]] wherein the condition is selected from a hyperproliferative condition, an inflammatory condition and cancer.

Claim 21-22 (canceled)